ToplineEuropean pharmaceutical giants Sanofi and GlaxoSmithKline on Monday said their next-generation Covid booster shot provoked a “strong immune response” against omicron and other variants of concern, promising news for the industry heavyweights as more companies vie to enter the maturing coronavirus vaccine market. Sanofi's booster shot generated strong immune response against variants of concern, the company ... [+] said. Sanofi also said an independent study conducted by the Assistance Publique-Hôpitaux de Paris showed its next-generation booster generated a stronger immune response against omicron than a booster shot of Pfizer’s original Covid vaccine for those already vaccinated with Pfizer’s shot. Though frontrunners like Moderna, Pfizer-BioNTech, Johnson & Johnson and AstraZeneca have enjoyed a powerful first-mover advantage, there is still a sizable market left for latecomers. Most major Covid vaccine makers—including Pfizer, Moderna, Johnson & Johnson and Novavax—have been working on newer shots to address fading effectiveness against omicron.

Source: Forbes June 13, 2022 17:18 UTC